These results indicate that venetoclax-resistant DLBCL cells have an increased dependence on ETC complex I and that acquired venetoclax resistance due to BCL2 mutation or intrinsic resistance from BCL2 expression loss does not confer this reliance. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.